An Debate Around Risky Abiraterone-Systems

We also report on measles-related deaths. For 2012, there were 27?134 measles cases and 29?601 rubella cases reported in the Region. For 2013, these figures were 31?520 and 39?367 Ixazomib ic50 respectively. Most measles cases in 2013 (96%; n?=?30?178) were reported by nine countries: Georgia (7830), Germany (1773), Italy (2216), the Netherlands (2499), Romania (1074), the Russian Federation (2174), Turkey (7404), Ukraine (3308) and the United Kingdom (1900). In 2013, most measles cases were among unvaccinated persons and over one in three patients were aged 20?years and older. For 2013, almost all rubella cases were reported by Poland (n?=?38?585; 98%). High population immunity and high-quality surveillance are the cornerstones to eliminate measles and rubella. Without sustained political commitment and accelerated action by Member States and partners, the elimination of measles and rubella in the WHO European Region may not be achieved. Despite substantial progress made towards controlling measles and rubella in the World Health Organization (WHO) European Region, the regional target of measles and rubella elimination by 2015 is in jeopardy. The Region comprises 53 Member States [1] that together have a population of just over 900 million. All countries use measles- and rubella-containing vaccines, usually in Abiraterone mouse combination with a mumps vaccine. To assess the status of measles and rubella in the Region in relation to the elimination target, we report on the number of measles and rubella cases in 2012 and review the epidemiological data on these diseases for 2013. We also discuss the current challenges faced and the actions needed to reach this goal. We report on the number of measles and rubella cases by country in 2012 and present an analysis of preliminary measles and rubella surveillance data for 2013, as of 31 January 2014. We analysed data submitted by national surveillance institutions to the Centralized Information System for Infectious Diseases (CISID) [2] of the WHO Regional Office for Europe. Data from the 28 Member States Thalidomide of the European Union, Iceland and Norway were entered into CISID after collection and processing by The European Surveillance System (TESSy), of the European Centre for Disease Prevention and Control [3]. We also report on measles and rubella virus sequence data as entered in the Measles Nucleotide Surveillance database (MeaNS) [4] and Rubella Nucleotide Surveillance database (RubeNS) [5], respectively, by national or reference laboratories of the WHO European Region as of 31 January 2014. We analysed cases of measles and rubella with disease onset dates in 2013 by age group, diagnosis confirmation and vaccination, hospitalization and importation status. Cases were separated by age: